- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Sanofi India concluded 2025 with a pivotal business model transformation aimed at sustainable, profitable growth.
**Business Performance:** For FY25, Net Sales saw a modest 1% YoY increase to ₹1,511.5 Cr, with Domestic Sales growing a healthy 6% to ₹1,468.3 Cr. Total Income dipped 9% to ₹1,857.1 Cr, primarily due to a 54% drop in Export Sales to ₹43.2 Cr. Despite this, Profit Before Tax (PBT) rose 1% to ₹472 Cr, boosted by operational efficiency and a 17% reduction in operating expenses.
**Growth Drivers & Strategy:** The company is strategically focused on transforming its Diabetes business, leveraging AI and digital capabilities to grow its Insulin franchise, where it holds a 31% market share. Key initiatives include portfolio optimization, market expansion into public sectors and Tier II/III cities, and customer-centric go-to-market strategies.
**Recent Developments:** Sanofi India achieved a major R&D milestone by completing 'Last Patient In' for its Soliqua RWE Phase IV study in December 2025. Its 2nd gen basal insulin, Toujeo, showed strong double-digit growth.
**Key Financial Metrics:** EPS for 2025 stood at ₹142, and the proposed dividend is ₹123 per share.
**Management Commentary / Outlook:** Sanofi views this transformation as complete, positioning it to capture India's significant diabetes market growth through operational excellence and future-ready capabilities.